Posted On: 01/28/2015 11:09:27 AM
Post# of 72750
$CELG Recent News
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Sara Sjolin
Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog 10:00 a.m. Today - Zacks.com
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog 6:55 p.m. Jan. 27, 2015 - Zacks.com
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog 6:30 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Do You Believe Me Now? 10:59 a.m. Jan. 27, 2015 - Seeking Alpha
Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog 10:19 a.m. Jan. 27, 2015 - Zacks.com
Celgene: Could You Be More Like Gilead, Please? 7:47 a.m. Jan. 27, 2015 - Seeking Alpha
Big Cap Stocks Mylan, American Tower Near Buy Points 5:42 p.m. Jan. 26, 2015 - Investors Business Daily
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog 12:00 p.m. Jan. 26, 2015 - Zacks.com
Zillow Is In Limbo - Cramer's Lightning Round (1/23/15) 7:42 a.m. Jan. 26, 2015 - Seeking Alpha
The Coming Week Is The Most Important - Cramer's Mad Money (1/23/15) 7:38 a.m. Jan. 26, 2015 - Seeking Alpha
Can CAR-T Therapy Live Up To The Biotech IPO Hype? 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
Apple, Facebook Lead This Week's IBD 50 Earnings 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
The Best Play in Biotechs: M&A 5:05 a.m. Jan. 26, 2015 - InvestorPlace.com
'Mad Money' Lightning Round: Constellation Brands the New King in Town 6:00 a.m. Jan. 24, 2015 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Jan. 23, 2015 - TheStreet.com
European Ad Comm supports expanded label for Abraxane 7:44 a.m. Jan. 23, 2015 - Seeking Alpha
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog 5:40 p.m. Jan. 22, 2015 - Zacks.com
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog 4:10 p.m. Jan. 22, 2015 - Zacks.com
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog 4:00 p.m. Jan. 22, 2015 - Zacks.com
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Sara Sjolin
Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog 10:00 a.m. Today - Zacks.com
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog 6:55 p.m. Jan. 27, 2015 - Zacks.com
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog 6:30 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Do You Believe Me Now? 10:59 a.m. Jan. 27, 2015 - Seeking Alpha
Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog 10:19 a.m. Jan. 27, 2015 - Zacks.com
Celgene: Could You Be More Like Gilead, Please? 7:47 a.m. Jan. 27, 2015 - Seeking Alpha
Big Cap Stocks Mylan, American Tower Near Buy Points 5:42 p.m. Jan. 26, 2015 - Investors Business Daily
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog 12:00 p.m. Jan. 26, 2015 - Zacks.com
Zillow Is In Limbo - Cramer's Lightning Round (1/23/15) 7:42 a.m. Jan. 26, 2015 - Seeking Alpha
The Coming Week Is The Most Important - Cramer's Mad Money (1/23/15) 7:38 a.m. Jan. 26, 2015 - Seeking Alpha
Can CAR-T Therapy Live Up To The Biotech IPO Hype? 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
Apple, Facebook Lead This Week's IBD 50 Earnings 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
The Best Play in Biotechs: M&A 5:05 a.m. Jan. 26, 2015 - InvestorPlace.com
'Mad Money' Lightning Round: Constellation Brands the New King in Town 6:00 a.m. Jan. 24, 2015 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Jan. 23, 2015 - TheStreet.com
European Ad Comm supports expanded label for Abraxane 7:44 a.m. Jan. 23, 2015 - Seeking Alpha
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog 5:40 p.m. Jan. 22, 2015 - Zacks.com
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog 4:10 p.m. Jan. 22, 2015 - Zacks.com
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog 4:00 p.m. Jan. 22, 2015 - Zacks.com
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
(0)
(0)
